Acquired microsatellite instability status and loss of HER2 positivity during treatment of gastro-esophageal junction adenocarcinoma

被引：0

作者：

Alexis, Lynn Gabrielle ^{[1
]}

Dano, Helene ^{[2
]}

Dekairelle, Anne-France ^{[3
]}

Van Marcke, Cedric ^{[1
]}

Van den Eynde, Marc ^{[4
,5
]}

机构：

[1] Univ Catholique Louvain UCLouvain, Inst Roi Albert II, Dept Med Oncol, Clin Univ St Luc, Brussels, Belgium

[2] Univ Catholique Louvain UCLouvain, Inst Roi Albert II, Dept Pathol, Clin Univ St Luc, Brussels, Belgium

[3] Univ Catholique Louvain UCLouvain, Inst Roi Albert II, Dept Genet, Clin Univ St Luc, Brussels, Belgium

[4] Univ Catholique Louvain UCLouvain, Inst Roi Albert II, Dept Med Oncol & Hepatogastroenterol, Clin Univ St Luc, Brussels, Belgium

[5] Clin Univ St Luc, Ave Hippocrate,10, B-1200 Brussels, Belgium

来源：

DIGESTIVE AND LIVER DISEASE | 2023年 / 55卷 / 03期

关键词：

HETEROGENEITY; EXPRESSION;

D O I：

10.1016/j.dld.2022.11.023

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：426 / 428

页数：3

共 50 条

[31] Valemetostat and trastuzumab deruxtecan (T-DXd) in previously treated advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastric cancer or gastro-esophageal junction (GEJ) adenocarcinoma.
Shitara, Kohei
Enzinger, Peter C.
Mohapatra, Avani
Janjigian, Yelena Y.
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS508 - TPS508
[32] Prognostic value of Lauren classification and C-erbB-2 oncogene overexpression in adenocarcinoma of the esophagus and gastro-esophageal junction
Polkowski, W
van Sandick, JW
Offerhaus, GJA
ten Kate, FJW
Obertop, H
van Lanschot, JJB
GASTROENTEROLOGY, 1998, 114 (04) : A663 - A663
[33] Thoracoabdominal gastrectomy and distal 2/3 esophageal resection with wide lymph node dissection for type II and III adenocarcinoma at the gastro-esophageal junction
Jeremiasen, Martin
Walther, Bruno
Djerf, Pauline
von Holstein, Christer Stael
Zilling, Thomas
Hermansson, Michael
Falkenback, Dan
Johansson, Jan
AMERICAN JOURNAL OF SURGERY, 2019, 218 (02): : 329 - 334
[34] PD-L1 as a predictive biomarker for pembrolizumab in HER2-positive gastric or gastro-esophageal junction adenocarcinoma-a commentary on KEYNOTE-811
Yu, James
Saeed, Anwaar
CHINESE CLINICAL ONCOLOGY, 2024, 13 (04)
[35] PTEN Loss Predicts Poor Response to Trastuzumab in HER2 Overexpressing Gastric or Esophageal Adenocarcinoma
Deguchi, Yasunori
Okabe, Hiroshi
Oshima, Nobu
Hisamori, Shigeo
Sakai, Yoshiharu
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2016, 223 (04) : E47 - E47
[36] Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study
Zaanan, Aziz
Palle, Juliette
Soularue, Emilie
Leroy, Florence
Louafi, Samy
Tougeron, David
Manfredi, Sylvain
Artru, Pascal
Pozet, Astrid
Taieb, Julien
TARGETED ONCOLOGY, 2018, 13 (01) : 107 - 112
[37] HER2 STATUS DOES NOT EXPLAIN THE DIFFERENCE IN AGGRESSIVE BEHAVIOR BETWEEN ESOPHAGEAL ADENOCARCINOMA PHENOTYPES
Sawas, Tarek
Iyer, Prasad G.
Wang, Kenneth K.
Katzk, David A.
GASTROENTEROLOGY, 2021, 160 (06) : S637 - S637
[38] Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study
Aziz Zaanan
Juliette Palle
Emilie Soularue
Florence Leroy
Samy Louafi
David Tougeron
Sylvain Manfredi
Pascal Artru
Astrid Pozet
Julien Taieb
Targeted Oncology, 2018, 13 : 107 - 112
[39] RAS/RAF mutations and microsatellite instability status in primary colorectal cancers according to HER2 amplification
Lee, Sun Mi
Oh, Hyunjoo
SCIENTIFIC REPORTS, 2024, 14 (01):
[40] Serum HER 2 Extracellular Domain Level Is Correlated with Tissue HER 2 Status in Metastatic Gastric or Gastro-Oesophageal Junction Adenocarcinoma
Dai, Shu-Qin
An, Xin
Wang, Fang
Shao, Qiong
Chen, Yong-Chang
Kong, Ya-Nan
Chen, Cui
Li, Cong
Luo, Hui-Yan
Liang, Ying
Wang, Feng-Hua
Xu, Rui-Hua
Li, Yu-Hong
PLOS ONE, 2013, 8 (05):

← 1 2 3 4 5 →